**Supplemental Table S1. Scenario 1 Market Shares by Previous Biologic or JAKi Exposure Status**

|  |  |  |  |
| --- | --- | --- | --- |
| **Drug Class** | **Drug Name** | **Biologic or JAKi-naïve** | **Biologic or JAKi-experienced** |
| T-cell activation | Abatacept IV | 6.74% | 8.17% |
| Abatacept SC | 3.17% | 4.15% |
| CD-20 | Rituximab IV | 4.70% | 6.93% |
| TNFi biologics | Adalimumab SC | 34.14% | 23.40% |
| Certolizumab pegol SC | 2.45% | 3.18% |
| Etanercept SC | 21.95% | 21.00% |
| Golimumab SC | 0.83% | 1.62% |
| Golimumab IV | 4.82% | 4.21% |
| Infliximab IV | 5.22% | 11.80% |
| Infliximab dyyb IV | 1.28% | 1.20% |
| JAKi | Tofacitinib PO | 10.01% | 8.87% |
| Baricitinib PO | 0.48% | 0.10% |
| IL-6 | Sarilumab SC | 0.75% | 0.57% |
| Tocilizumab IV | 1.57% | 2.12% |
| Tocilizumab SC | 1.54% | 2.36% |
| IL-1 | Anakinra SC | 0.33% | 0.30% |

Abbreviations: IV, intravenous; SC, subcutaneous; TNFi, tumor necrosis factor inhibitors; JAKi, Janus kinase inhibitor; PO, oral; IL, interleukin.